toggle visibility Search & Display Options

Select All    Deselect All
 |   | 
Details
   print
  Records Links
Author Mukerji, R.; Kakarala, R.; Smith, S.J.; Kusz, H.G. url  doi
openurl 
  Title Chryseobacterium indologenes: an emerging infection in the USA Type Journal Article
  Year 2016 Publication BMJ Case Reports Abbreviated Journal BMJ Case Rep  
  Volume (down) 2016 Issue Pages  
  Keywords Anti-Bacterial Agents/therapeutic use; Chryseobacterium/isolation & purification; Cross Infection/*diagnosis/*drug therapy; Flavobacteriaceae Infections/*diagnosis/*drug therapy; Geriatric Nursing; Humans; Male; Middle Aged; Nursing Homes; Precision Medicine; Treatment Outcome; United States  
  Abstract Nursing home-associated infections and antibiotic resistant pathogens constitute common and serious problems in the geriatric population.Chryseobacterium indologenes, a non-motile Gram-negative rod, though widely distributed in nature, is an uncommon human pathogen. Typically thought of as an organism of low virulence, it may cause serious infections, particularly among the immunocompromised. The majority of reported cases are nosocomial, often associated with immunosuppression or indwelling catheters. It has been reported as the causative agent in bacteraemia, peritonitis, pneumonia, empyema, pyelonephritis, cystitis, meningitis and central venous catheter-associated infections. We report a rare case of C. indologenesinfection affecting a nursing home resident in the USA and we provide a review of similar cases. This report emphasises the importance of individualised treatment and promotes awareness about this organism as one of several emerging pathogens in immunocompromised adults and in the frail elderly who are often nursing home residents, in the Western Hemisphere.  
  Address Graduate Medical Education/Internal Medicine, McLaren-Flint Health Center/Michigan State University, Flint, Michigan, USA  
  Corporate Author Thesis  
  Publisher Place of Publication Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume Series Issue Edition  
  ISSN 1757-790X ISBN Medium  
  Area Expedition Conference  
  Notes PMID:27053540 Approved no  
  Call Number ref @ user @ Serial 99152  
Permanent link to this record
 

 
Author Mukerji, R.; Kakarala, R.; Smith, S.J.; Kusz, H.G. url  doi
openurl 
  Title Chryseobacterium indologenes: an emerging infection in the USA Type Journal Article
  Year 2016 Publication BMJ Case Reports Abbreviated Journal BMJ Case Rep  
  Volume (down) 2016 Issue Pages  
  Keywords Anti-Bacterial Agents/therapeutic use; Chryseobacterium/isolation & purification; Cross Infection/*diagnosis/*drug therapy; Flavobacteriaceae Infections/*diagnosis/*drug therapy; Geriatric Nursing; Humans; Male; Middle Aged; Nursing Homes; Precision Medicine; Treatment Outcome; United States  
  Abstract Nursing home-associated infections and antibiotic resistant pathogens constitute common and serious problems in the geriatric population.Chryseobacterium indologenes, a non-motile Gram-negative rod, though widely distributed in nature, is an uncommon human pathogen. Typically thought of as an organism of low virulence, it may cause serious infections, particularly among the immunocompromised. The majority of reported cases are nosocomial, often associated with immunosuppression or indwelling catheters. It has been reported as the causative agent in bacteraemia, peritonitis, pneumonia, empyema, pyelonephritis, cystitis, meningitis and central venous catheter-associated infections. We report a rare case of C. indologenesinfection affecting a nursing home resident in the USA and we provide a review of similar cases. This report emphasises the importance of individualised treatment and promotes awareness about this organism as one of several emerging pathogens in immunocompromised adults and in the frail elderly who are often nursing home residents, in the Western Hemisphere.  
  Address Graduate Medical Education/Internal Medicine, McLaren-Flint Health Center/Michigan State University, Flint, Michigan, USA  
  Corporate Author Thesis  
  Publisher Place of Publication Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume Series Issue Edition  
  ISSN 1757-790X ISBN Medium  
  Area Expedition Conference  
  Notes PMID:27053540 Approved no  
  Call Number ref @ user @ Serial 100182  
Permanent link to this record
 

 
Author Medrano, L.M.; Taxonera, C.; Gonzalez-Artacho, C.; Pascual, V.; Gomez-Garcia, M.; Barreiro-de Acosta, M.; Perez-Calle, J.L.; Bermejo, F.; Lopez-Sanroman, A.; Martin Arranz, D.; Gisbert, J.P.; Mendoza, J.L.; Martin, J.; Nunez, C.; Urcelay, E. url  doi
openurl 
  Title Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile Type Journal Article
  Year 2015 Publication Mediators of Inflammation Abbreviated Journal Mediators Inflamm  
  Volume (down) 2015 Issue Pages 318207  
  Keywords  
  Abstract Substantial proportion of Crohn's disease (CD) patients shows no response or a limited response to treatment with infliximab (IFX) and to identify biomarkers of response would be of great clinical and economic benefit. The expression profile of five genes (S100A8-S100A9, G0S2, TNFAIP6, and IL11) reportedly predicted response to IFX and we aimed at investigating their etiologic role through genetic association analysis. Patients with active CD (350) who received at least three induction doses of IFX were included and classified according to IFX response. A tagging strategy was used to select genetic polymorphisms that cover the variability present in the chromosomal regions encoding the identified genes with altered expression. Following genotyping, differences between responders and nonresponders to IFX were observed in haplotypes of the studied regions: S100A8-S100A9 (rs11205276(*)G/rs3014866(*)C/rs724781(*)C/rs3006488(*)A; P = 0.05); G0S2 (rs4844486(*)A/rs1473683(*)T; P = 0.15); TNFAIP6 (rs11677200(*)C/rs2342910(*)A/rs3755480(*)G/rs10432475(*)A; P = 0.10); and IL11 (rs1126760(*)C/rs1042506(*)G; P = 0.07). These differences were amplified in patients with colonic and ileocolonic location for all but the TNFAIP6 haplotype, which evidenced significant difference in ileal CD patients. Our results support the role of the reported expression signature as predictive of anti-TNF outcome in CD patients and suggest an etiological role of those top-five genes in the IFX response pathway.  
  Address Immunology Department, Hospital Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), 28040 Madrid, Spain  
  Corporate Author Thesis  
  Publisher Place of Publication Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume Series Issue Edition  
  ISSN 0962-9351 ISBN Medium  
  Area Expedition Conference  
  Notes PMID:26339133 Approved no  
  Call Number ref @ user @ Serial 73726  
Permanent link to this record
 

 
Author Lin, Z.; Liao, Z.; Huang, J.; Ai, M.; Pan, Y.; Wu, H.; Lu, J.; Cao, S.; Li, L.; Wei, Q.; Tang, D.; Wei, Y.; Li, T.; Wu, Y.; Xu, M.; Li, Q.; Jin, O.; Yu, B.; Gu, J. url  doi
openurl 
  Title Predictive Factors of Clinical Response of Infliximab Therapy in Active Nonradiographic Axial Spondyloarthritis Patients Type Journal Article
  Year 2015 Publication BioMed Research International Abbreviated Journal Biomed Res Int  
  Volume (down) 2015 Issue Pages 876040  
  Keywords  
  Abstract Objectives. To evaluate the efficiency and the predictive factors of clinical response of infliximab in active nonradiographic axial spondyloarthritis patients. Methods. Active nonradiographic patients fulfilling ESSG criteria for SpA but not fulfilling modified New York criteria were included. All patients received infliximab treatment for 24 weeks. The primary endpoint was ASAS20 response at weeks 12 and 24. The abilities of baseline parameters and response at week 2 to predict ASAS20 response at weeks 12 and 24 were assessed using ROC curve and logistic regression analysis, respectively. Results. Of 70 axial SpA patients included, the proportions of patients achieving an ASAS20 response at weeks 2, 6, 12, and 24 were 85.7%, 88.6%, 87.1%, and 84.3%, respectively. Baseline MRI sacroiliitis score (AUC = 0.791; P = 0.005), CRP (AUC = 0.75; P = 0.017), and ASDAS (AUC = 0.778, P = 0.007) significantly predicted ASAS20 response at week 12. However, only ASDAS (AUC = 0.696, P = 0.040) significantly predicted ASAS20 response at week 24. Achievement of ASAS20 response after the first infliximab infusion was a significant predictor of subsequent ASAS20 response at weeks 12 and 24 (wald chi (2) = 6.87, P = 0.009, and wald chi (2) = 5.171, P = 0.023). Conclusions. Infliximab shows efficiency in active nonradiographic axial spondyloarthritis patients. ASDAS score and first-dose response could help predicting clinical efficacy of infliximab therapy in these patients.  
  Address Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-Sen University, Tianhe Road No. 600, Guangzhou 510630, China  
  Corporate Author Thesis  
  Publisher Place of Publication Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume Series Issue Edition  
  ISSN 2314-6141 ISBN Medium  
  Area Expedition Conference  
  Notes PMID:26273654 Approved no  
  Call Number ref @ user @ Serial 73732  
Permanent link to this record
 

 
Author Guo, Y.; Zhou, G.; He, C.; Yang, W.; He, Z.; Liu, Z. url  doi
openurl 
  Title Serum Levels of Lipopolysaccharide and 1,3-beta-D-Glucan Refer to the Severity in Patients with Crohn's Disease Type Journal Article
  Year 2015 Publication Mediators of Inflammation Abbreviated Journal Mediators Inflamm  
  Volume (down) 2015 Issue Pages 843089  
  Keywords  
  Abstract OBJECTIVES: Interactions between the host and gut microbial community contribute to the pathogenesis of Crohn's disease (CD). In this study, we aimed to detect lipopolysaccharide (LPS) and 1,3-beta-D-glucan (BG) in the sera of CD patients and clarify the potential role in the diagnosis and therapeutic approaches. MATERIALS AND METHODS: Serum samples were collected from 46 patients with active CD (A-CD), 22 CD patients at remission stage (R-CD), and 20 healthy controls, and the levels of LPS, BG, and TNF in sera were determined by ELISA. Moreover, sixteen patients with A-CD received anti-TNF monoclonal antibody therapy (infliximab, IFX) at a dose of 5 mg/kg body weight at weeks 0, 2, and 6, and the levels of LPS and BG were also tested at week 12 after the first intravenous infusion. RESULTS: Serum levels of LPS and BG were found to be markedly increased in A-CD patients compared with R-CD patients and healthy controls (P < 0.05). They were also observed to be positively correlated with CDAI, ESR, and SES-CD, respectively (P < 0.05). Furthermore, the levels of TNF in sera had a significant correlation with LPS and BG, respectively. The concentrations of LPS and BG were demonstrated to be significantly downregulated in the sera of A-CD patients 12 weeks after IFX treatment (P < 0.05), suggesting that blockade of TNF could inhibit bacterial endotoxin absorption, partially through improving intestinal mucosal barrier. CONCLUSIONS: Serum levels of LPS and BG are significantly increased in A-CD patients and positively correlated with the severity of the disease. Blockade of intestinal mucosal inflammation with IFX could reduce the levels of LPS and BG in sera. Therefore, this study has shed some light on measurement of serum LPS and BG in the diagnosis and treatment of CD patients.  
  Address Department of Gastroenterology, Shanghai Tenth People's Hospital of Tongji University, Shanghai 200072, China  
  Corporate Author Thesis  
  Publisher Place of Publication Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume Series Issue Edition  
  ISSN 0962-9351 ISBN Medium  
  Area Expedition Conference  
  Notes PMID:26106258 Approved no  
  Call Number ref @ user @ Serial 73762  
Permanent link to this record
Select All    Deselect All
 |   | 
Details
   print

Save Citations:
Export Records: